First In Human Study Of Increasing Oral Doses Of PF-04634817

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Healthy
Interventions
DRUG

PF-04634817 Placebo

Oral solution, placebo, single dose

DRUG

PF-04634817

Oral solution, 1mg, single dose

DRUG

PF-04634817

Oral solution, 3mg, single dose

DRUG

PF-04634817

Oral solution, 10mg, single dose

DRUG

PF-04634817

Oral solution, 30mg, single dose

DRUG

PF-04634817

Oral solution, 100mg, single dose

DRUG

PF-04634817

Oral solution, 300mg, single dose

DRUG

PF-04634817

Oral solution, 600mg, single dose

DRUG

PF-04634817

Oral solution, 900mg, single dose

DRUG

PF-04634817

Oral solution, up to 900mg, single dose after food

DRUG

PF-04634817 Placebo

Oral solution, placebo, single dose after food

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01098877 - First In Human Study Of Increasing Oral Doses Of PF-04634817 | Biotech Hunter | Biotech Hunter